Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Apr;98(16):e15335.
doi: 10.1097/MD.0000000000015335.

A meta-analysis on the prognosis of exosomal miRNAs in all solid tumor patients

Jiupeng Zhou  1 , Hui Guo  2 , Yuanli Yang  1 , Yongfeng Zhang  1 , Heng Liu  1
Affiliations
Meta-Analysis

A meta-analysis on the prognosis of exosomal miRNAs in all solid tumor patients

Jiupeng Zhou et al. Medicine (Baltimore). 2019 Apr.

Abstract

Background: It has been reported that the encapsulated miRNAs from exosomes are potential biomarkers of tumors prognosis. Yet, the results are controversial, so it is obliged to do a meta-analysis to reach a definite conclusion.

Materials and methods: Studies were searched for published in PubMed, Embase, and Web of Science databases until April 20, 2018. A meta-analysis was conducted to appraise the role of exosomal miRNAs in prognosis of cancer patients.

Results: The different exosomal miRNAs expression was remarkably related to overall survival (OS) (hazard ratio [HR] = 2.02, 95% confidence interval [CI]: 1.84-2.21) and disease-free survival (DFS) (HR = 2.43, 95% CI: 1.86-3.17) of cancer patients. High exosomal miR-21 expression was associated with poor OS (HR = 2.59; 95% CI: 1.71-3.90) and DFS (HR = 1.84; 95% CI: 1.37-2.47). High exosomal miR-451a expression was associated with poor OS (HR = 4.81; 95% CI: 2.33-9.93) and DFS (HR = 2.64; 95% CI: 1.62-4.31). High exosomal miR-1290 expression was associated with poor OS (HR = 1.73; 95% CI: 1.29-2.33). Low exosomal miR-638 expression was associated with poor OS (HR = 2.25; 95% CI: 1.46-3.46).

Conclusion: The expression levels of exosomal miRNAs, particularly miR-21, miR-451a, miR-1290, and miR-638 could strongly predict prognosis of solid tumor patients and might be a potential target for tumor treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
A flowchart presenting the steps of literature retrieval and selection.
Figure 2
Figure 2
A forest plot for the association between the exosomal miRNA expression levels with OS. OS = overall survival.
Figure 3
Figure 3
A forest plot for the association between the exosomal miRNA expression levels with DFS. DFS = disease-free survival.
Figure 4
Figure 4
A subgroup analysis for the association between the exosomal miRNA expression levels with OS. OS = overall survival.
Figure 5
Figure 5
A subgroup analysis for the association between the exosomal miRNA expression levels with DFS. DFS = disease-free survival.
Figure 6
Figure 6
A funnel plot analysis of potential publication bias A: OS; B: DFS. OS = overall survival, DFS = disease-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yi R, Li Y, Wang FL, et al. MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol 2016;8:330–40. - PMC - PubMed
    1. Deng D, Liu Z, Du Y. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet 2010;71:125–76. - PubMed
    1. Peinado H, Lavotshkin AM, MateiI S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med 2012;18:883–91. - PMC - PubMed
    1. Tovar-Camargo OA, Toden S, Goel A. Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers. Expert Rev Mol Diagn 2016;16:553–67. - PMC - PubMed
    1. Dejima H, Iinuma H, Kanaoka R, et al. Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncol Lett 2017;13:1256–63. - PMC - PubMed